You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 
  1. EVENTS - 22-10-2018

    50 years of Anti-D celebrated at World Congress of Gynecology and Obstetrics in Rio De Janeiro

    Kedrion supports educational symposium to help Rh disease awareness and eradication

    read more 
  2. EVENTS - 18-10-2018

    EIGHT, the global educational initiative on Hemophilia A and its treatment

    Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

    read more 
  3. EVENTS - 02-10-2018

    Kedrion Biopharma participates in the Mother and Child Conference in Moscow

    A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

    read more 
  4. CORPORATE - 05-09-2018

    Kedrion joins Rhesus Solution Initiative (RSI) symposium in Lagos

    Nigeria to advocate for Rh Disease universal eradication

    read more 

Pages

For more information please contact: pressoffice@kedrion.com